This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Incyte (INCY) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Incyte's (INCY) fourth-quarter 2022 earnings are likely to have gained from higher Jakafi sales and incremental sales from newly approved drugs.
Can Sanofi (SNY) Keep the Beat Streak Alive in Q4 Earnings?
by Zacks Equity Research
Sanofi's (SNY) top line is likely to have been driven by higher sales of Dupixent and vaccines.
Will Eylea and Dupixent Fuel Regeneron's (REGN) Q4 Earnings?
by Zacks Equity Research
Regeneron's (REGN) fourth-quarter earnings are likely to have gotten a boost from the solid performances of Eylea and Dupixent.
Eli Lilly (LLY) Lymphoma Candidate Pirtobrutinib Gets FDA Nod
by Zacks Equity Research
The FDA approves Eli Lilly's Jaypirca (pirtobrutinib) under an accelerated approval pathway as a treatment for mantle cell lymphoma (MCL).
Merck (MRK) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda when the company reports Q4 earnings.
Beat the Market the Zacks Way: NVIDIA, Bilibili, Novo Nordisk in Focus
by Abhinab Dasgupta
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.
Weibo and Viasat have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Weibo and Viasat are part of the Zacks Bull and Bear of the Day article.
Eli Lilly (LLY) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Higher demand for its key drugs is likely to have offset generic competition for several other drugs and may have boosted Lilly's (LLY) fourth-quarter sales.
How Did COVID Reshape the Labor Markets
by John Blank
The latest research focuses on retirees.
Is a Beat on the Cards for Novo Nordisk (NVO) in Q4 Earnings?
by Zacks Equity Research
Novo Nordisk's (NVO) top line is likely to have been driven by sales of its Diabetes and Obesity Care products in the fourth quarter of 2022.
Can Pfizer (PFE) Beat Expectations This Earnings Season?
by Zacks Equity Research
Higher alliance revenues from Eliquis, higher sales of Prevnar vaccines and drugs like Vyndaqel/Vyndamax are likely to have contributed to Pfizer's (PFE) sales growth in Q4.
Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Gilead (GILD) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports its fourth-quarter 2022 results.
Novartis' (NVS) Unit to Acquire Astellas' Rights of Mycamine
by Zacks Equity Research
Novartis' (NVS) generic unit Sandoz is set to acquire rights to the antifungal product Mycamine from Astellas.
J&J (JNJ) Q4 Earnings Beat, Sales Miss, 2023 EPS View Upbeat
by Zacks Equity Research
J&J (JNJ) beats estimates for fourth-quarter earnings but misses the same for sales. Its EPS outlook for 2023 is above expectations while sales fall short.
Novo Nordisk (NVO) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Novo Nordisk (NVO) closed at $141.08, marking a -0.01% move from the previous day.
3 Reasons Growth Investors Will Love Novo Nordisk (NVO)
by Zacks Equity Research
Novo Nordisk (NVO) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Here's How Much a $1000 Investment in Novo Nordisk Made 10 Years Ago Would Be Worth Today
by Zacks Equity Research
Holding on to popular or trending stocks for the long-term can make your portfolio a winner.
J&J (JNJ) to Begin Q4 Earnings Season for Pharma Sector
by Zacks Equity Research
Growth in J&J's (JNJ) Pharma unit is expected to have been driven by drugs like Darzalex and Stelara. In the MedTech segment, continued recovery in worldwide procedure volume should drive sales.
Novo Nordisk (NVO) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Novo Nordisk (NVO) closed at $138.98 in the latest trading session, marking a +1.95% move from the prior day.
Zacks.com featured highlights include Oxford Industries, Ingredion, Novo Nordisk, Helmerich & Payne and Fox Factory Holdings
by Zacks Equity Research
Oxford Industries, Ingredion, Novo Nordisk, Helmerich & Payne and Fox Factory Holdings are part of the Zacks Screen of the Week article.
SNY vs. NVO: Which Stock Is the Better Value Option?
by Zacks Equity Research
SNY vs. NVO: Which Stock Is the Better Value Option?
Bet on These 5 Low Leverage Stocks Amid Easing Inflation
by Aparajita Dutta
A prudent investor knows that if one wants to avoid huge losses in times of crisis, one needs to look for relatively safe bets. You may buy OXM, INGR, NVO, HP & FOXF.
Beat the Market the Zacks Way: Oracle, NVIDIA, Kimberly-Clark in Focus
by Abhinab Dasgupta
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.
State of California Sues Insulin Makers for Unfair Practices
by Zacks Equity Research
The lawsuit aims to curb the skyrocketing cost of insulin charged by insulin manufacturers and pharmacy benefit managers companies. The State also seeks to recover some monetary compensation.